skip to content


Abzena notes acquisition of True North Therapeutics

24 May 2017 08:07

Abzena has noted the announcement from Bioverativ that it has entered into a definitive agreement to acquire True North Therapeutics for an upfront payment of $400 million plus assumed cash.

It said that True North investors were also eligible to receive additional payments of up to $425 million contingent on the achievement of future development, regulatory and sales milestones. As part of the acquisition, Bioverativ will obtain worldwide rights to True North Therapeutics' lead candidate, TNT009, a first-in-class monoclonal antibody in development to treat cold agglutinin disease (CAD).

CAD is a rare and chronic haemolytic condition that often leads to severe anaemia, requiring numerous transfusions, and can result in life-threatening thrombotic events.

There are no approved therapies for CAD, which occurs in approximately 16 people per million globally, including an estimated 5,000 people in the United States.

TNT009 was created using Abzena's Composite Human Antibody technology and falls within the Abzena Inside portfolio of products being developed by Abzena's partners.

At 8:07am: (LON:ABZA) Abzena Plc share price was +3.25p at 37.25p

Story provided by

Related Company: ABZA

Info Point:

To buy or sell shares call our Dealing Room on 0113 243 6941.

Too much jargon? Our glossary will help make sense of things.

Find out more about our Share Dealing Services.

Client Area Access

» Secure Login

» Not registered yet?


Branch Finder

Redmayne-Bentley have High Street branches throughout the UK. Find your nearest branch.